Rho Announces Kristen Harrington’s Appointment to President of Southeast SAS® Users Group (SESUG)
Chapel Hill, NC ̶ November 8, 2018 Rho, a full-service contract research organization (CRO) focused on bringing new products to market through a full range of product development services, today announced that Principal Programmer/Analyst and Statistical Programming Operational Service Lead Kristen Harrington has been appointed to President of SESUG, a Regional Users Group (RUG) for users of SAS® Software. Her appointment term begins January 1, 2019.
In her role as president, Kristen will lead the SESUG Executive Council. To qualify for the appointment of president, the person must be a prior SESUG conference co-chair. Kristen is currently the vice president (term began Jan. 1, 2018), and has also served as treasurer (term began Jan 1, 2017). Additionally, she has been a member of the Executive Council since 2014 and was conference co-chair in 2016. She has attended, volunteered and presented at SESUG since 2007.
“What an honor it is to be named president of SESUG. I have enjoyed serving as the vice president over the last year and I am ready for the challenge of leading the Executive Council in my new role,” said Kristen. As a veteran user of SAS® software, I have valued my involvement with SESUG for more than a decade and I look forward to an exciting year of education and networking opportunities.”
Kristen has more than 19 years of experience using SAS® software for data analysis including more than 16 years working in clinical trials and drug development. At Rho, she serves as an internal expert in statistical programming and leads teams of statistical programmers.
To learn more about Rho, please visit www.rhoworld.com.
Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For more than 35 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. Please follow us on Twitter.